Brooklyn Immunotherapeutics Inc
Change company Symbol lookup
Select an option...
BTX Brooklyn Immunotherapeutics Inc
SBCF Seacoast Banking Corporation of Florida
MSSAU Metal Sky Star Acquisition Corp
SDGR Schrodinger Inc
GPC Genuine Parts Co
VENA Venus Acquisition Corp
VECO Veeco Instruments Inc
IGTAU Inception Growth Acquisition Ltd
BAC-K Bank of America Corp
FAX abrdn Asia-Pacific Income Fund Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Closing Price
$0.2303
Day's Change
-0.0319 (-12.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.2993
Day's Low
0.2303
Volume
(Heavy Day)
Volume:
1,727,500

10-day average volume:
815,612
1,727,500

SHAREHOLDER ALERT: Weiss Law Reminds ZEN, EVOP, RMO, and RFP Shareholders About Its Ongoing Investigations

1:19 pm ET August 5, 2022 (PR Newswire) Print

https://mma.prnewswire.com/media/1424445/WeissLaw_LLP_Logo.jpg

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin, Esq.Weiss Law305 Broadway, 7th FloorNew York, NY 10007(212) 682-3025(888) 593-4771stockinfo@weisslawllp.com

Zendesk, Inc. (NYSE: ZEN)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zendesk, Inc. (NYSE: ZEN), in connection with the proposed acquisition of ZEN by investment firms Permira and Hellman & Friedman LLC. Under the terms of the merger agreement, ZEN shareholders will receive $77.50 in cash for each share of ZEN common stock owned. If you own ZEN shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/zen

EVO Payments, Inc. (NASDAQ: EVOP)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of EVO Payments, Inc. (NASDAQ: EVOP), in connection with the proposed acquisition of EVOP by Global Payments Inc. Under the terms of the merger agreement, EVOP shareholders will receive $34.00 in cash for each share of EVOP common stock owned. If you own EVOP shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/evop

Romeo Power, Inc. (NYSE: RMO)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Romeo Power, Inc. (NYSE: RMO), in connection with the proposed acquisition of RMO by Nikola Corporation ("Nikola") via tender offer. Under the terms of the merger agreement, RMO shareholders will receive 0.1186 shares of Nikola common stock for each RMO share owned, representing implied per-share merger consideration of approximately $0.89 based upon Nikola's August 4, 2022 closing price of $7.48. If you own RMO shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/rmo

Resolute Forest Products Inc. (NYSE: RFP)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Resolute Forest Products Inc. (NYSE: RFP) in connection with the proposed acquisition of RFP by The Paper Excellence Group, through its wholly-owned subsidiary Domtar Corporation ("Domtar"). The transaction will be carried out by way of a merger of RFP with a newly created subsidiary of Domtar, providing for conversion of each share of RFP common stock into the right to receive $20.50 per share, together with a Contingent Value Right ("CVR") entitling the holder to a share of future softwood lumber duty deposit refunds. If you own RFP shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/rfp

https://c212.net/c/img/favicon.png?sn=DC37683&sd=2022-08-05

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-reminds-zen-evop-rmo-and-rfp-shareholders-about-its-ongoing-investigations-301600852.html

SOURCE Weiss Law

https://rt.prnewswire.com/rt.gif?NewsItemId=DC37683&Transmission_Id=202208051319PR_NEWS_USPR_____DC37683&DateId=20220805

comtex tracking

COMTEX_411683909/1005/2022-08-05T13:19:07

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.